ICIs, which include anti‐programmed cell death‐1 (PD‐1) and anti‐PD‐1 ligand (PD‐L1) antibodies, are widely used in the treatment of solid and hematological malignancies to improve overall survival and serve as an important treatment option for advanced cancers.2, 3. Here, CD274 is linked to hematologic disorder.